Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
Authors
Wang Yk
Department of Early Drug Development Center, Peking University Cancer Hospital & Institute, Beijing, China;
Wang Yk , Jifang Gong , Yuping Sun , Jian Zhang , Shuqin Ni , Jie Hou , Xiaohua Chen , Yusheng Wang , Qin Yu , Xiangdong Qu , Yejie Du , Li Wei , Tao Yu , Lin Shen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04856150
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 382)
DOI
10.1200/JCO.2023.41.4_suppl.382
Abstract #
382
Poster Bd #
G4
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase I trial of sequential dosing of sonidegib and pembrolizumab in advanced solid tumors (aST) and non–small-cell lung cancer (NSCLC).
First Author: Mohamed Shanshal
Poster
2023 ASCO Annual Meeting
Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.
First Author: Brian Ko
Poster
2022 ASCO Annual Meeting
A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors.
First Author: Toshio Shimizu
Poster
2022 ASCO Annual Meeting
Safety results of Q-1802, a Claudin18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors in a phase 1 study.
First Author: Jifang Gong